# Genetics, phenotype, Aging "Style," rapamycin **URL:** \ **Category:** General\ **Created:** [June 27, 2024, 11:08am UTC](https://www.rapamycin.news/t/genetics-phenotype-aging-style-rapamycin/14704 "2024-06-27T11:08:56Z")\ **Posts on this page:** 1\ **Showing post:** 6
**Author:** ![59vw](https://www.rapamycin.news/user_avatar/www.rapamycin.news/59vw/32/35163_2.png) [@59vw](https://www.rapamycin.news/u/59vw)\ **Post date:** [June 27, 2024, 7:45pm UTC](https://www.rapamycin.news/t/genetics-phenotype-aging-style-rapamycin/14704/6 "2024-06-27T19:45:18Z")
Many of us here are concerned about dementia. I think your thoughts (anabolic vs catabolic) are interesting and worth thinking about. I’m not sure rapamycin fits into one model or the other though. Many on this group take rapa primarily to prevent dementia, most commonly alzheimers. The proposed mechanism of alzheimers being inflammatory breakdown of the blood brain barrier and rapa proposed to subvert this process through various pathways. Some of this is nicely substantiated in animal models of Alzheimers though most animal models of this disease are poor approximations of the human condition. There are clinical trials underway to study the affect of rapamycin on alzheimers development in humans. > [@Evaluating the affect of Rapamycin in Alzheimer's disease (ERAP phase IIa clinical study protocol)](https://www.rapamycin.news/t/evaluating-the-affect-of-rapamycin-in-alzheimers-disease-erap-phase-iia-clinical-study-protocol/13852): > > Reading this protocol is a nice summary of evidence to date for the use of Rapamycin to treat/prevent Alzheimer’s. I couldn’t find that someone else had posted this study protocol that came out in April 2024. --- _[View the full topic](https://www.rapamycin.news/t/genetics-phenotype-aging-style-rapamycin/14704)._